Canada IBD Therapeutics market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease, 120,000 with ulcerative colitis, and 15,000 with IBD type unclassified (IBD-U). CCC further estimates that seven out of every 1,000 Canadians have IBD. Moreover, by 2030, the number of people living with IBD is expected to rise to over 400,000, or nearly 1% of the population. The highest reported incidence of IBD is in Nova Scotia at 54.6 per 100,000 new cases per year, and the lowest is in British Columbia at 18.7 per 100,000 people per year. The incidence of IBD in Alberta, Manitoba, Ontario, Quebec, and Saskatchewan are similar, ranging from 21.6 to 28.3 per 100,000 people per year.

Request a Free Sample of our Canada Inflammatory Bowel Disease (IBD) Therapeutics Market: https://www.omrglobal.com/request-sample/canada-ibd-inflammatory-bowel-disease-therapeutics-market

Canada IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. For Crohn’s and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.

A full Report of Canada Inflammatory Bowel Disease (IBD) Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/canada-ibd-inflammatory-bowel-disease-therapeutics-market

Canada Inflammatory bowel Disease IBD Therapeutics Market Segmentation

By Disease Type

• Ulcerative Colitis
• Crohn’s Disease

By Treatment Type

• Surgery
• Anti- Inflammatory Drug Administration
• Steroids
• Immunosuppressant
• Biological Drugs
• Amino salicylates
• Others

Company Profiles

• Abbott Laboratories
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Celgene Corp.
• Eli Lilly and Co.
• Johnson & Johnson Services Inc.
• Laboratory Corporation of America Holdings
• Pfizer Inc.
• Sanofi S.A.
• Takeda pharmaceutical Co., Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/canada-ibd-inflammatory-bowel-disease-therapeutics-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404